

Sun Pharma response to import ban lack sufficient corrective actions: USFDA

21 May 2014 | News | By BioSpectrum Bureau

Sun Pharma response to import ban lack sufficient corrective actions: USFDA



U.S. Food and Drug Administration said in a warning letter that Sun Pharmaceutical Industries Ltd's response to an import ban on one of its plants lacked "sufficient corrective actions."

Report stated that USFDA banned imports from Sun Pharma's Karkhadi plant in Gujarat in March.

Sun Pharma failed to ensure laboratory records had complete data and that manufacturing staff had inadequate training and experience, FDA was quoted as saying.

The Karkhadi plant, which makes the antibiotic cephalosporin, is one of Sun Pharma's 25 manufacturing plants.